Arisara Phuwajaroanpong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Arisara Phuwajaroanpong has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Atthaphon Konyanee
Center of Excellence in Tropical Pathobiology, Walailak University, Nakhon Si Thammarat 80160, Thailand
2 shared publications - Chuchard Punsawad
Center of Excellence in Tropical Pathobiology, Walailak University, Nakhon Si Thammarat 80160, Thailand
2 shared publications - Prapaporn Chaniad
Center of Excellence in Tropical Pathobiology, Walailak University, Nakhon Si Thammarat 80160, Thailand
2 shared publications - Walaiporn Plirat
Center of Excellence in Tropical Pathobiology, Walailak University, Nakhon Si Thammarat 80160, Thailand
2 shared publications - Abdi Wira Septama
Research Center for Pharmaceutical Ingredient and Traditional Medicine, National Research and Innovation Agency (BRIN), KST Soekarno, Cibinong, Jawa Barat, 16911, Indonesia
1 shared publication - Ahmad Ghazali Ismail
School of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden 11800, Pulau Pinang, Malaysia
1 shared publication
Latest Publications
- Open Access
In Vitro and In Vivo Antiplasmodial Activities, Phytochemical Characterization, and Acute Oral Toxicity of Leaf Extracts of Blumea balsamifera
Blumea balsamifera is traditionally used in Thai herbal remedies for fever management; however, its antiplasmodial potential has not been comprehensively investigated. In this study, we evaluated the in vitro and in vivo antiplasmodial activities, phytochemical profile, and acute oral toxicity of B. balsamifera leaf extracts. Antiplasmodial activity against Plasmodium falciparum K1 and cytotoxicity against Vero cells were determined using the parasite lactate dehydrogenase (pLDH) assay and an MTT assay, respectively. Phytochemical constituents of the ethanolic extract were characterized by liquid chromatography–quadrupole time-of-flight mass spectrometry (LC-QTOF-MS). In vivo antiplasmodial assessment was investigated in Plasmodium berghei ANKA-infected mice using Peters’ four-day suppressive test at oral doses of 200, 400, and 600 mg/kg. Acute oral toxicity was evaluated following a single oral dose of 2000 mg/kg. The ethanolic extract exhibited promising in vitro antiplasmodial activity, with an IC50 value of 2.65 µg/mL and a selectivity index (SI) of 23.03, whereas the aqueous extract was inactive (IC50 > 40 µg/mL). LC-QTOF-MS analysis of the ethanolic leaf extract tentatively identified 16 compounds in the negative ionization mode and 30 compounds in the positive ionization mode. In the four-day suppressive test, the ethanolic extract demonstrated dose-dependent antiplasmodial activity, with parasitemia suppression of 42.29%, 70.74%, and 76.54% at doses of 200, 400, and 600 mg/kg, respectively. In the acute toxicity study, no mortality, abnormal clinical signs, or significant changes in body weight, food consumption, or water intake were observed. Furthermore, no evidence of hepatotoxicity or nephrotoxicity was detected. The ethanolic leaf extract of B. balsamifera demonstrated antiplasmodial activity in both in vitro and in vivo models, with favorable selectivity and no apparent acute toxicity at the tested dose. These findings support the potential of B. balsamifera as a source of antiplasmodial compounds and provide a basis for further phytochemical isolation and mechanistic studies.
Open AccessIn Vitro and In Vivo Antiplasmodial Activities, Phytochemical Characterization, and Acute Oral Toxicity of Leaf Extracts of Blumea balsamifera
Blumea balsamifera is traditionally used in Thai herbal remedies for fever management; however, its antiplasmodial potential has not been comprehensively investigated. In this study, we evaluated the in vitro and in vivo antiplasmodial activities, phytochemical profile, and acute oral toxicity of B. balsamifera leaf extracts. Antiplasmodial activity against Plasmodium falciparum K1 and cytotoxicity against Vero cells were determined using the parasite lactate dehydrogenase (pLDH) assay and an MTT assay, respectively. Phytochemical constituents of the ethanolic extract were characterized by liquid chromatography–quadrupole time-of-flight mass spectrometry (LC-QTOF-MS). In vivo antiplasmodial assessment was investigated in Plasmodium berghei ANKA-infected mice using Peters’ four-day suppressive test at oral doses of 200, 400, and 600 mg/kg. Acute oral toxicity was evaluated following a single oral dose of 2000 mg/kg. The ethanolic extract exhibited promising in vitro antiplasmodial activity, with an IC50 value of 2.65 µg/mL and a selectivity index (SI) of 23.03, whereas the aqueous extract was inactive (IC50 > 40 µg/mL). LC-QTOF-MS analysis of the ethanolic leaf extract tentatively identified 16 compounds in the negative ionization mode and 30 compounds in the positive ionization mode. In the four-day suppressive test, the ethanolic extract demonstrated dose-dependent antiplasmodial activity, with parasitemia suppression of 42.29%, 70.74%, and 76.54% at doses of 200, 400, and 600 mg/kg, respectively. In the acute toxicity study, no mortality, abnormal clinical signs, or significant changes in body weight, food consumption, or water intake were observed. Furthermore, no evidence of hepatotoxicity or nephrotoxicity was detected. The ethanolic leaf extract of B. balsamifera demonstrated antiplasmodial activity in both in vitro and in vivo models, with favorable selectivity and no apparent acute toxicity at the tested dose. These findings support the potential of B. balsamifera as a source of antiplasmodial compounds and provide a basis for further phytochemical isolation and mechanistic studies.
- Open Access
- 4 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (17) , 7892
Antiplasmodial Compounds from Eurycoma harmandiana Pierre and Eurycoma longifolia Jack Against Drug-Resistant Plasmodium falciparum: An Integrated In Vitro and In Silico Study
Malaria is a life-threatening global disease, and despite artemisinin-based combination therapies (ACTs) as first-line treatment, emerging drug-resistant Plasmodium strains necessitate novel antimalarial agents. This study investigated the antiplasmodial potential of Eurycoma harmandiana Pierre (EH) root extract, a medicinal plant closely related to Eurycoma longifolia Jack (EL). The extract and its derived compounds were evaluated using in vitro antiplasmodial and cytotoxicity assays. The active compounds were further investigated by parasite morphological analysis, molecular docking against quadruple-mutant Plasmodium falciparum dihydrofolate reductase (qmPfDHFR), molecular dynamics (MD) simulations, and in silico prediction of drug-likeness, pharmacokinetic properties, and toxicity. The ethanolic extract exhibited potent antiplasmodial activity (IC50 = 0.51 µg/mL) with low cytotoxicity (CC50 = 31.68 µg/mL) and a high selectivity index (SI = 62.11). Quassinoids showed the strongest activity (IC50 = 0.13–0.87 µM), whereas alkaloids displayed good to moderate activity. The extract and two promising bioactive quassinoids, eurycomanone (1) and glaucarubolone (5), disrupted intraerythrocytic parasite development. Molecular docking and MD simulations demonstrated that glaucarubolone (5) exhibited favorable predicted interactions with qmPfDHFR, along with favorable predicted drug-like properties, pharmacokinetic profiles, and low toxicity. This study provides the first report of the antiplasmodial activity of Eurycoma harmandiana, highlighting it as a promising alternative source of bioactive compounds against Plasmodium parasites. Glaucarubolone (5) may represent a promising scaffold for further investigation toward the development of novel antimalarial agents.
- 4 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (17) , 7892
Open AccessAntiplasmodial Compounds from Eurycoma harmandiana Pierre and Eurycoma longifolia Jack Against Drug-Resistant Plasmodium falciparum: An Integrated In Vitro and In Silico Study
Malaria is a life-threatening global disease, and despite artemisinin-based combination therapies (ACTs) as first-line treatment, emerging drug-resistant Plasmodium strains necessitate novel antimalarial agents. This study investigated the antiplasmodial potential of Eurycoma harmandiana Pierre (EH) root extract, a medicinal plant closely related to Eurycoma longifolia Jack (EL). The extract and its derived compounds were evaluated using in vitro antiplasmodial and cytotoxicity assays. The active compounds were further investigated by parasite morphological analysis, molecular docking against quadruple-mutant Plasmodium falciparum dihydrofolate reductase (qmPfDHFR), molecular dynamics (MD) simulations, and in silico prediction of drug-likeness, pharmacokinetic properties, and toxicity. The ethanolic extract exhibited potent antiplasmodial activity (IC50 = 0.51 µg/mL) with low cytotoxicity (CC50 = 31.68 µg/mL) and a high selectivity index (SI = 62.11). Quassinoids showed the strongest activity (IC50 = 0.13–0.87 µM), whereas alkaloids displayed good to moderate activity. The extract and two promising bioactive quassinoids, eurycomanone (1) and glaucarubolone (5), disrupted intraerythrocytic parasite development. Molecular docking and MD simulations demonstrated that glaucarubolone (5) exhibited favorable predicted interactions with qmPfDHFR, along with favorable predicted drug-like properties, pharmacokinetic profiles, and low toxicity. This study provides the first report of the antiplasmodial activity of Eurycoma harmandiana, highlighting it as a promising alternative source of bioactive compounds against Plasmodium parasites. Glaucarubolone (5) may represent a promising scaffold for further investigation toward the development of novel antimalarial agents.